The emergence of WT1-specific T-cell responses following allogeneic T cell-depleted hematopoietic stem cell transplantation and low-dose donor lymphocyte infusions is associated with a graft-vs.- myeloma effect.
The development of T-cell responses specific for myeloma-associated antigens correlates with improved clinical outcomes in multiple myeloma patients undergoing allogeneic T cell-depleted hematopoietic stem cell transplantation and donor lymphocyte infusions. Thus, immunotherapeutic strategies that further increase the frequency of Wilms tumor 1 (WT1)-specific T cells may provide clinical benefits to multiple myeloma patients.
Immunology and Microbial Pathogenesis Program; Weill Cornell Graduate School of Medical Sciences; New York, NY USA ; Sloan-Kettering Institute; New York, NY USA.
Eleanor M
EM
Tyler
Guenther
G
Koehne
WT1-specific cytotoxic T cells; allogeneic stem cell transplantation; donor lymphocyte infusion; graft-vs.-myeloma effect; multiple myeloma